We use cookies to improve the performance of our site and optimize it for our users. Customize Cookie Preferences

Sign Up Today and Learn More About Novelty Nobility Stock

Invest in or calculate the value of your shares in Novelty Nobility or other pre-IPO companies through EquityZen's platform.

Get Started

Novelty Nobility Stock (NONO)

Novelty Nobility is a private biotech company focused on the research of novel angiogenesis targets and develop antibody-based therapeutics.

About Novelty Nobility Stock

Founded

2017

Industries

Software, Artificial Intelligence, Data and Analytics

Novelty Nobility Inc. is a private biotech company. They are currently focused on the research of novel angiogenesis targets and develop antibody-based therapeutics in ophthalmology and oncology, where angiogenesis plays a key pathogenic role. In ophthalmology, Novelty Nobility first discovered a novel angiogenesis target, Stem Cell Factor(SCF) and c-KIT, which was initially known for its engagement with proliferation and survival of primitive hematopoietic stem cells for a couple of past decades. We believe that anti-SCF/c-KIT could effectively address the unmet medical needs, mostly caused by inherent limitations of anti-VEGFs, in terms of treatment efficacy and long-term safety. Our target discovery is widely and strongly patent-protected in US/KOR and the lead pipeline, NN2101(a full-human monoclonal antibody), is currently under preclinical development.

Novelty Nobility Management

Leadership team at Novelty Nobility

Chief Finance & Business Officer

Jin Cho

Founder & CEO

Sang Gyu Park

Locked Features

Join now and verify your accreditation status to gain access to:

  • Novelty Nobility current valuation
  • Novelty Nobility stock price
  • Available deals in Novelty Nobility and all other companies
  • Deal offering documents
  • EquityZen's proprietary data and insights, including
    • Cap tables, which include funding history by Share Class and Liquidity Preferences
    • Company Highlights
    • Business Model
    • Risk Factors
Join Now

How to invest in Novelty Nobility stock?

Accredited investors can buy pre-IPO stock in companies like Novelty Nobility through EquityZen funds. These investments are made available by existing Novelty Nobility shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.

How to sell Novelty Nobility stock?

Shareholders can sell their Novelty Nobility stock through EquityZen's private company marketplace. EquityZen's network includes over 330K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.

If I invest, how do I exit my investment?

There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.

Why choose EquityZen?

Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 43K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."